Clinical Trials
209 trialsComparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer
Radiation Therapy Oncology Group
MULTISARC
Institut National de la Santé Et de la Recherche Médicale, France
National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
University of Birmingham
STERIMGLI
Institut Claudius Regaud
ASTEROID
Vastra Gotaland Region
ATLANTIC
AstraZeneca
358
Brown University
TRADE-hypo
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)
National Institutes of Health Clinical Center (CC)
Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
CAIRE
Institut Bergonié
Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours
AstraZeneca
Hepatic Artery Infusion Chemotherapy (HAIC) Plus Durvalumab for Advanced Hepatocellular Carcinoma
Sun Yat-sen University
Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck
AstraZeneca
Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin
National Cancer Institute (NCI)
A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC)
Memorial Sloan Kettering Cancer Center
DREAM3R
PrECOG, LLC.
Phase II Study of Durvalumab ,Doxorubicin, and Ifosfamide in Pulmonary Sarcomatoid Carcinoma
Seoul National University Hospital
......SMARTEST Trial......
University Health Network, Toronto
IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers
Abramson Cancer Center at Penn Medicine
ARION
UNICANCER
LCD
University of Kentucky
Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors
University of Kentucky
Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer
Washington University School of Medicine
Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)
Swiss Cancer Institute
SAVIMMUNE
Intergroupe Francophone de Cancerologie Thoracique
SEPION
GWT-TUD GmbH
Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial
National Cancer Institute (NCI)
Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
M.D. Anderson Cancer Center
Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients
Massachusetts General Hospital
SKYSCRAPER-03
Hoffmann-La Roche
TRAMUNE
Institut Bergonié
CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies
ModernaTX, Inc.
Trial in Patients With Relapsed Ovarian Cancer
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
CheckMate73L
Bristol-Myers Squibb
Radiotherapy With Durvalumab Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma
University of Colorado, Denver
Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes
M.D. Anderson Cancer Center
LUMINANCE
AstraZeneca
Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer
Canadian Cancer Trials Group
Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma
Thomas Jefferson University
ABIMMUNE
Gustave Roussy, Cancer Campus, Grand Paris
SAKK 06/17
Swiss Cancer Institute
Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
TopDouble
AstraZeneca
Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer
University of Texas Southwestern Medical Center
Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours
Canadian Cancer Trials Group
ICRA
The Netherlands Cancer Institute